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ABSTRACT 
Objective  
To determine if serum levels of endothelial adhesion molecules are associated with 
development of multiple organ failure (MOF) and in-hospital mortality in adult patients 
with severe sepsis.  
Design 
This study was a secondary data analysis of a prospective cohort study.   
Setting 
Patients were admitted to two tertiary intensive care units in San Antonio, TX, between 
2007 and 2012. 
Patients 
Patients with severe sepsis at the moment of ICU admission were enrolled. Inclusion 
criteria were consistent with previously published criteria for severe sepsis or septic 
shock in adults. Exclusion criteria included immunosuppressive medications or 
conditions. 
Interventions 
None. 
Measurements  
Baseline endothelial adhesion molecules serum levels of Intracellular Adhesion Molecule 
1 (ICAM-1), Vascular Cell Adhesion Molecule-1 (VCAM-1) and Vascular Endothelial 
Growth Factor (VEGF) were obtained within 24-48 hours of development of organ 
dysfunction. The primary outcome was development of MOF (>2 organ dysfunction) and 
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the secondary outcome was in-hospital mortality. 
Main results 
Forty-eight patients were enrolled in this study, of which 29 (60%) developed MOF. Severe 
septic patients that developed MOF had higher levels of VCAM-1 (p<0.01) and ICAM-1 
(p<0.02), but not VEGF levels (p=0.7). The area under the curve (AUC) to predict MOF 
according to VCAM-1, ICAM-1 and VEGF was 0.71, 0.73, and 0.54, respectively. Only 
VCAM-1 was associated with in-hospital mortality (p<0.04). These associations were 
maintained even after controlling for APACHE scores using logistic regression. 
Conclusions  
High levels of VCAM-1 and ICAM-1 were associated with the development of MOF. 
VCAM-1 levels are associated with in-hospital mortality. Further studies should evaluate 
the diagnostic and prognostic role of these biomarkers in septic patients. 
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INTRODUCTION 
Mortality rates for patients with severe sepsis and septic shock range from 40-60%, 
costing the U.S. health care system $17 billion annually1. Research is needed to identify 
patients with severe sepsis to expedite initiation of effective treatments. Hemodynamic 
parameters and lactate levels are useful in predicting multiple organ failure (MOF) in 
patients with sepsis, but only change when organ perfusion is already compromised2,3.  
Early clinical deterioration and death is related with a complex interaction between 
inflammation and coagulation that leads to organ dysfunction4. Among organ dysfunction, 
vascular endothelial damage plays an important role by increasing vascular permeability, 
activating the coagulation cascade and compromising regional perfusion in peripheral 
organs (e.g. kidneys, liver, gut, etc.)5. Different methods have been proposed to assess 
vascular endothelial damage in patients with sepsis6. However, biomarkers may potentially 
help in determining the presence of vascular endothelial injury and its associated with the 
development of MOF and mortality.  
The cell adhesion molecules (CAMs) are a group of trans-membrane proteins that 
are responsible of the cell adhesion process. These proteins allow cell to interact with the 
extracellular matrix (ECM), their own cytoskeleton and other cells7. In the vascular 
endothelium, these proteins are responsible of maintain the homeostasis and interact with 
circulation cells7. The three CAMs that have been used as biomarkers of vascular 
endothelial injury are Vascular Endothelial Growth Factor (VEGF), Intracellular Adhesion 
Molecule 1 (ICAM-1), and Vascular Cell Adhesion Molecule-1 (VCAM-1). ICAM-1 and 
VCAM-1 are cell present in the membranes of leukocytes and vascular endothelium, 
allowing inflammatory cells to transmigrate into nearby tissues7. These adhesion molecules 
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are expressed in large quantities in patients with sepsis and other uncontrolled 
inflammatory states8. They contribute to endothelial surface damage and vascular leakage5. 
VEGF directly influences endothelial fenestrations, with high levels causing vascular 
leakage9. Previous studies have shown that higher serum levels of ICAM-1 and VCAM-1 
are associated with more severe forms of neonatal sepsis 10. Similarly, ICAM-1 gene 
deletions in mice have been associated with improved mortality and less histological 
evidence of organ damage compared to controls with sepsis 5. Limited data are available 
regarding the role of ICAM-1 and VCAM-1 in patients with sepsis. In addition, studies 
evaluating VEGF’s role in sepsis have not produced consistent results 11,12. Therefore, more 
studies are needed to evaluate the role of these biomarkers in predicting outcomes of sepsis. 
ICAM-1, VCAM-1 and VEGF play an important role in vascular endothelial 
integrity and have a potential clinical application to predict disease progression and clinical 
outcomes in patients with sepsis. The objective of this study is to determine if elevated 
levels of endothelial adhesion molecules are associated with (MOF) and increased in-
hospital mortality in adult patients with severe sepsis and septic shock. If higher levels are 
indeed associated with poor outcomes, then rising levels of these markers can be used to 
predict clinical deterioration and could be used as potential diagnostic tool and therapeutic 
targets.  
 
 
 
 
MATERIAL AND METHODS 
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Study Design 
 This study is a secondary analysis of a cohort of patients admitted to the intensive 
care unit (ICU) for severe sepsis or septic shock at two hospitals (South Texas Veterans 
Health Care System and University Hospital, San Antonio, TX), between 2007 and 2012. 
The study was approved by the local institutional review board (HSC20070713H), and is 
posted on www.clinicaltrials.gov (NCT00708799). All participants signed a consent form 
before entry into the study. 
 Inclusion criteria for enrollment included age >18 years, informed written consent 
was obtained from the patient/patient’s legal representative, and criteria for severe sepsis 
or septic shock were met 13. Exclusion criteria were prolonged QT intervals, medications 
associated with increased QT intervals, or history of arrhythmias. Patients who were 
immunosuppressed were also excluded which was defined as: 1) Chemotherapy within the 
last one month, 2) Leukemia/lymphoma not in remission, 3) Solid organ or bone marrow 
stem cell transplant, 4) HIV with CD4 <200cells/mm3, and 5) Chronic steroid use defined 
as > 10mg/day of prednisone. 
 
Enrollment and Follow-Up 
 All patients were screened for eligibility at the time of admission to the ICU and 
followed daily until hospital discharge. An Acute Physiology and Chronic Health 
Evaluation (APACHE II) score was obtained for each patient during the first 24-hours of 
admission to the ICU 14.  
 
Clinical Outcomes 
 8 
 The primary outcome of this study was development of MOF and the secondary 
outcome was in-hospital mortality.  
 
Biomarkers and Assays 
Venous blood was drawn from patients between 24-48 hours of developing MOF. 
Serum ICAM-1, VCAM-1 and VEGF were measured using a commercially available 
Human Inflammation Panel kit from Luminex Technology that was analyzed at Myriad 
Rules Based Medicine Inc. (Austin Texas.)  
 
Statistical Analysis 
 Categorical variables were compared between groups using Fisher’s exact test. 
Continuous variables were evaluated using non-parametric analysis using Man-Whitney U 
Test. Values are expressed as median (IQR). Statistical significance was defined as p-value 
< 0.05. A receiver operating characteristic (ROC) curve was developed to assess the 
accuracy of ICAM-1, VCAM-1 and VEGF to predict outcomes. Multivariate analysis was 
performed using multiple logistic regression to evaluate the relation of serum levels of 
ICAM-1, VCAM-1 and VEGF with the proposed outcomes after adjust the analysis with 
the APACHE score. All statistical analyses were performed with IBM SPSS, Statistics for 
Windows, version 22.0. Armonk, NY: IBM Crop. 
 
 
 
RESULTS 
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Patient characteristics 
Forty-eight patients were included in the study cohort, of which 29 (60%) 
developed MOF.  Tables 1 in patient’s demographic characteristics were no statistically 
differences between the two groups such as age, gender, comorbid-conditions, sources of 
infection, or previous medication use. Severe septic patients with MOF had higher median 
(IQR) APACHE II scores on admission (21[15,28] vs. 19[14,21]; p=0.04) compared with 
those without MOF. 
 
Outcomes 
Patients with severe sepsis that developed MOF had higher levels of VCAM-1 
(median [IQR] 1,090 ng/mL [789, 1,410] vs. 1,690 ng/mL [1,065, 3,590]; p=0.007) and 
ICAM-1 (258 ng/mL [199, 341] vs. 362 ng/mL [270, 449]; p=0.01) compared to patients 
with single organ failure (Figure 1). This association was maintained even after controlling 
for APACHE II scores in the logistic regression. Figure 2 shows the number of cases of 
MOF and its relation with the serum levels of VCAM-1, ICAM-1 and VEGF. The area 
under the curve (AUC) for VCAM-1’s association with MOF was 0.71 (Figure 3), and the 
AUC for ICAM-1 association with MOF was 0.73. There was no statistically significant 
association between VEGF and the development of MOF (p=0.7).  
Only higher VCAM-1 levels showed a statistically significant association with in-
hospital mortality (median [IQR] 1,240 ng/mL [806, 1,882] vs. 2,210 ng/mL [1,500, 
3,432]; p=0.03). This association was maintained even after controlling for APACHE II 
scores in the logistic regression. The AUC for VCAM’s association with in-hospital 
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mortality is presented in figure 3. There was no statistically significant association between 
ICAM-1 and VEGF with hospital mortality.  
 
DISCUSSION 
High levels of VCAM-1 and ICAM-1 were found to be associated with the 
development of MOF in patients with severe sepsis and septic shock. In this same patient 
population, only high VCAM-1 level was associated with in-hospital mortality. These 
associations were maintained even after logistic regression and controlling for overall 
severity of illness with APACHE II scores. VEGF level was not found to be predictive of 
MOF or in-hospital mortality.  
 Previous studies have shown that VCAM-1 is present in low concentrations in the 
membranes of leukocytes, macrophages, and vascular endothelial cells5. Infection 
increases transcription of VCAM-1 which is expressed on vascular endothelial surfaces5. 
Leukocytes activated by inflammatory mediators bind to the VCAM-1 endothelial surface 
receptors and translocate into local tissues to combat infection5. During states of diffuse 
and uncontrolled inflammation, as in sepsis, VCAM-1 is expressed in large quantities.  The 
ensuing leukocyte adhesion and associated inflammatory cascade have been linked to 
vascular endothelial damage, capillary leakage, and organ dysfunction5. Several in-vitro 
studies have demonstrated this phenomenon, but few clinical studies have evaluated the 
significance of elevated VCAM-1 levels in sepsis.  One study in neonates demonstrated 
higher levels of VCAM-1 associated with more severe forms of sepsis and MOF15. These 
findings are consistent with our study that found elevated serum levels of VCAM-1 at the 
onset of organ dysfunction predicted development of MOF in adult patients with severe 
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sepsis and septic shock. However, there is a paucity of data evaluating the association of 
VCAM-1 levels with the clinical outcome of mortality.  Our study was novel in that in-
hospital mortality was assessed, and in-hospital mortality was indeed associated with 
higher VCAM-1 levels.  
 During inflammatory states, ICAM-1 has the same role as VCAM-1 as a vascular 
endothelial surface receptor allowing leukocytes and other inflammatory cells to bind and 
translocate into local tissues5. Thus, ICAM-1 plays a similar role in capillary leakage and 
organ dysfunction when the normal localized inflammatory cascade becomes 
uncontrolled5. Considering these similarities to VCAM-1, previous studies have shown that 
higher levels of ICAM-1 are associated with severe sepsis and MOF in neonates10. 
Furthermore, multiple mouse models have shown that ICAM-1 knockout mice with severe 
forms of sepsis have lower mortality rates5,16.  Our finding that higher levels of ICAM-1 
predict development of MOF in patients with severe sepsis and septic shock is a novel 
finding in the adult population.   
In contrast to studies with mouse models, ICAM-1 levels were not associated with 
increased in-hospital mortality in our sample of adult patients with severe sepsis and septic 
shock. A lack of statistical association may be due to the small sample size of our study. 
Another possibility is the role of VCAM-1 may be more pronounced in the inflammatory 
cascade than ICAM-1 and therefore, VCAM-1 levels were found to correlate with vascular 
endothelial damage and poor clinical outcomes. However this speculation requires further 
testing to confirm. 
 Similar to VCAM-1 and ICAM-1, VEGF also plays an integral role in the integrity 
of vascular endothelium. VEGF has been shown to induce the expression of both VCAM-
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1 and ICAM-1, and contribute to vascular endothelial damage and capillary leakage due to 
up-regulation during sepsis17. Unlike VCAM-1 and ICAM-1, VEGF has a multitude of 
other roles. In adults with sepsis, high VEGF levels have been shown to increase vascular 
permeability by binding to the tyrosine-protein kinase receptor-1 (FLT-1), altering the 
configuration of endothelial actin filaments, and increasing fenestrations in the 
endothelium18.  Consequently, the vascular endothelium is made susceptible to damage, 
ultimately resulting in organ dysfunction18. FLT-1 receptor blockers/anti-VEGF receptor 
antibodies have been shown to decrease mortality in septic mice18. VEGF also has a 
procoagulant effect, causing microthrombi in peripheral vasculature18. Considering these 
plausible associations of elevated VEGF levels with increased sepsis severity vascular 
damage, human clinical studies have yielded less consistent results on mortality11,12. In 
contrast, in our study VEGF levels were not associated with MOF or mortality, but were 
consistent with the study done by Karlsson et al. 2008 12, who had a sample size of 215 
patients with severe sepsis and septic shock.  Although our sample size may explain the 
lack of an association between VEGF and clinically important outcomes, Van Der Flier et 
al. in 2005 showed a positive association of VEGF levels and mortality in a sample size of 
only 18 septic adult patients11. Baseline patient characteristics may explain these findings, 
but further investigation is required. Of important note, Jiang et al. 201419 found that 
VEGF-to-Platelet ratio was predictive of 28-day mortality in patients with sepsis in China, 
illustrating the need to further investigation. 
 Our study has some limitations.  That includes the limited of well-characterized 
group of patients with severe sepsis and septic shock. Generalization of these results 
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requires further exploration in larger cohorts. Several other mechanisms may be associated 
to the development of MOF beyond the endothelial adhesion molecules. 
 
CONCLUSIONS   
High levels of VCAM-1 and ICAM-1 at the onset of acute organ dysfunction are 
associated with the development of MOF, with high VCAM-1 levels also associated with 
higher in-hospital mortality. These biomarkers have the potential to assist in early 
recognition and initiation of appropriate therapies to ultimately improve clinical outcomes.  
Further studies are needed to investigate the role of VCAM-1, ICAM-1, and VEGF as 
prognostic markers in patients with sepsis. Unlike the non-specific therapeutic targets of 
corticosteroids and statins, these biomarkers have specific receptors that warrant further 
investigation as potential therapeutic targets to attenuate the inflammatory cascade during 
sepsis. 
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Figure legends 
Figure 1.  Boxplots representing serum levels of VCAM-1 (Panel A), ICAM-1 (Panel B) 
and VEGF (Panel C) according to multiorgan failure (MOF) and survival status.  
 
Figure 2. Distribution of VACM-1, ICAM-1 and VEGF levels by the number of subjects 
according to the presence or absence of multiorgan failure (MOF).   
 
Figure 3. ROC curves of VCAM-1 (Panel A), ICAM-1 (Panel B) and VEGF (Panel C) 
predict multi organ failure (MOF) and hospital mortality.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 18 
Tables  
Table 1. Baseline characteristics of patients with severe sepsis stratified according to the 
presence of multiorgan failure (MOF) 
                                  
 
Characteristic 
 
No MOF 
(n=19) 
 
MOF 
(n=29) 
 
p 
Value 
Demographic  
Male 19 (100) 27 (93) 0.6 
Age, mean (IQR*) 59 (51, 65) 58 (45, 79) 0.6 
Comorbid conditions, n (%)  
Obesity  7 (37) 12 (41) 0.5 
Active cancer 2 (10) 0 (0) 0.2 
Prior cancer 3 (16) 5 (17) 0.6 
Cardiovascular disease  7 (37) 5 (17) 0.1 
Chronic heart failure  3 (16) 1 (3) 0.2 
COPD 3 (16) 3 (10) 0.4 
Chronic kidney disease 3 (16) 2 (7) 0.3 
Depression  2 (10) 7 (24) 0.2 
Diabetes mellitus  10 (53) 13 (45) 0.4 
HIV 1 (5) 0 (0) 0.7 
Hyperlipidemia  4 (17) 1 (3) 0.6 
Leukemia  1 (5) 0 (0) 0.4 
Liver disease  1 (5) 2 (7) 0.6 
Tobacco use  6 (32) 8 (28) 0.5 
Alcohol use  4 (21) 7 (24) 0.5 
Asthma 1 (5) 3 (10) 0.5 
Source of infection, n (%)     
Pulmonary  7 (37) 8 (28) 0.5 
Urinary tract  6 (32) 10 (34) 0.3 
GI 2 (10) 4 (14) 0.4 
Skin  3 (16) 5 (17) 0.3 
Endocarditis  0 (0) 1 (3) 0.9 
    
* IQR, interquartile range 
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Figure 1. 
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Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  
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